Acquisitions
Every acquisition, minority investment and growth investment we hold, clearly labelled from source rows. The Overview summarizes these deal events alongside investment filings and news.
1,250 rows · acquisitions · newest first · showing the latest 60Advanced filters
| Filed | Deal | Size | Sector | Buyer | Type | Src | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-28 | Boundless Bio, Inc. Buyer: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-27 | Forte Biosciences, Inc. Buyer: No captured description yet. | $0.001 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-21 | Werewolf Therapeutics, Inc. Buyer: No captured description yet. | $150 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-18 | BIOMARIN PHARMACEUTICAL INCBMRN ↗ → Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy Buyer: No captured description yet. Target: No captured description yet. | $275 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-17 | Talkspace, Inc.TALK ↗ → Talkspace, Inc Buyer: No captured description yet. Target: No captured description yet. | $17.4 billion | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-17 | DocGo Inc.DCGO ↗ → Hicuity Buyer: No captured description yet. Target: No captured description yet. | $50 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-17 | Fulcrum Therapeutics, Inc. Buyer: No captured description yet. | $245 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-14 | Skye Bioscience, Inc. Buyer: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-13 | Freenome, Inc. Buyer: Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone. | $0.0001 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-11 | MIMEDX GROUP, INC.MDXG ↗ → Sanara MedTech Inc. Buyer: No captured description yet. Target: No captured description yet. | $0.001 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-10 | Jazz Pharmaceuticals plcJAZZ ↗ → Knight Acquisition Corp. Buyer: No captured description yet. Target: No captured description yet. | $820,000,000 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-10 | Park Dental Partners, Inc. → Village Family Dental Services Organization Buyer: No captured description yet. Target: No captured description yet. | NA | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | Ensysce Biosciences, Inc.ENSC ↗ → Cy Biopharma, Inc Buyer: No captured description yet. Target: No captured description yet. | $77 Million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | Ensysce Biosciences, Inc.ENSC ↗ → Cy Biopharma, Inc Buyer: No captured description yet. Target: No captured description yet. | $77 Million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | Tarsus Pharmaceuticals, Inc.TARS ↗ → Alkeus Pharmaceuticals, Inc. Buyer: No captured description yet. Target: No captured description yet. | $270,000,000, | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | Tarsus Pharmaceuticals, Inc. Buyer: No captured description yet. | $125.0 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | HARROW, INC. → TYRVAYA® Buyer: No captured description yet. Target: No captured description yet. | $30 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | iRhythm Holdings, Inc. Buyer: No captured description yet. | $237.5 million | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-08-06 | iRhythm Holdings, Inc.IRTC ↗ → Vital Connect, Inc Buyer: No captured description yet. Target: No captured description yet. | $287.5 million | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-08-04 | Galera Therapeutics, Inc. → Obsidian Therapeutics, Inc. Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-04 | Lantheus Holdings, Inc.LNTH ↗ → Curium US Holdings LLC Buyer: No captured description yet. Target: No captured description yet. | NA | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-08-04 | Integer Holdings CorpITGR ↗ → Armstrong Parent, Inc. Buyer: No captured description yet. Target: No captured description yet. | NA | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-08-03 | Indivior Pharmaceuticals, Inc.INDV ↗ → Supernus continuing as the surviving corporation Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-03 | SUPERNUS PHARMACEUTICALS, INC. Buyer: No captured description yet. | $125 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-08-03 | Obsidian Therapeutics, Inc. Buyer: No captured description yet. | $350 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-30 | Vireo Growth Inc. → Planet 13 Holdings Inc. Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-29 | Processa Pharmaceuticals, Inc.PCSA ↗ → Vidya Therapeutics, Inc Buyer: No captured description yet. Target: No captured description yet. | $200 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-29 | SYNLOGIC, INC. Buyer: No captured description yet. | $278 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-29 | MIMEDX GROUP, INC.MDXG ↗ → Sanara MedTech Inc. Buyer: No captured description yet. Target: No captured description yet. | $0.001 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-29 | Processa Pharmaceuticals, Inc.PCSA ↗ → Vidya Therapeutics, Inc Buyer: No captured description yet. Target: No captured description yet. | $200 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-28 | First Choice Healthcare Solutions, Inc. → Westin Acquisition Corp Buyer: No captured description yet. Target: No captured description yet. | $650 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-28 | Yarrow Bioscience, Inc. Buyer: No captured description yet. | $200 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-28 | Yarrow Bioscience, Inc. Buyer: No captured description yet. | $200 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-28 | STANDARD BIOTOOLS INC.FLDM ↗ → Standard BioTools’ SomaLogic business Buyer: No captured description yet. Target: No captured description yet. | $30 Million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-27 | Forte Biosciences, Inc.FBRX ↗ → Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline Buyer: No captured description yet. Target: No captured description yet. | $77 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-24 | Neuphoria Therapeutics Inc.NEUP ↗ → Neuphoria. Upon completion of the Transaction, the combined company plans to operate Buyer: No captured description yet. Target: No captured description yet. | $89 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-24 | Neuphoria Therapeutics Inc.NEUP ↗ → Neuphoria. Upon completion of the Transaction, the combined company plans to operate Buyer: No captured description yet. Target: No captured description yet. | $89 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-22 | Repligen CorporationRGEN ↗ → BioLife Solutions, Inc. Buyer: No captured description yet. Target: No captured description yet. | $1.5 billion | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-22 | BIOLIFE SOLUTIONS INCBLFS ↗ → BioLife Solutions, Expanding Its Cell Therapy Capabilities Buyer: No captured description yet. Target: No captured description yet. | $1.5 billion | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-20 | Personalis, Inc.PSNL ↗ → Tempus AI, Inc. Buyer: No captured description yet. Target: No captured description yet. | $48.42, | AI | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-17 | Jasper Therapeutics, Inc.JSPR ↗ → Kira Pharmaceuticals Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-17 | Jasper Therapeutics, Inc.JSPR ↗ → Kira Pharmaceuticals Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-17 | Kuva Labs Inc. → Lisata Therapeutics, Inc. Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-16 | CATALYST PHARMACEUTICALS, INC.CPRX ↗ → Angelini Pharma S.p.A., an Italian Societ Buyer: No captured description yet. Target: No captured description yet. | $0.001 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-16 | Eli Lilly and CompanyLLY ↗ → AtaiBeckley Inc. Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-16 | Quantum Cyber N.V.QUCY ↗ → Manufacturing facility, Bridgeport, Connecticut Buyer: No captured description yet. Target: No captured description yet. | $2,300,000 | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-15 | Nuvalent, Inc.NUVL ↗ → GlaxoSmithKline LLC Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-15 | Celadon (via NewCo) → Senti Biosciences, Inc. (Gene-Circuit assets) Buyer: No captured description yet. Target: No captured description yet. | $60 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-15 | Celadon (via NewCo) → Senti Biosciences, Inc. (Gene-Circuit assets) Buyer: No captured description yet. Target: No captured description yet. | $60 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-14 | Ligand Pharmaceuticals IncorporatedLGND ↗ → XOMA Royalty Corporation Buyer: No captured description yet. Target: No captured description yet. | $739 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-14 | Ligand Pharmaceuticals IncorporatedLGND ↗ → XOMA Royalty Corporation Buyer: No captured description yet. Target: No captured description yet. | $739 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-14 | Avere Therapeutics (via merger) → NextCure, Inc. Buyer: No captured description yet. Target: No captured description yet. | $320 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-13 | Essence Parent Inc. → Esperion Therapeutics, Inc. Buyer: No captured description yet. Target: No captured description yet. | $100 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-13 | Essence Parent Inc. → Esperion Therapeutics, Inc. Buyer: No captured description yet. Target: No captured description yet. | $100 million | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-13 | Matinas BioPharma Holdings, Inc.MTNB ↗ → GH Power to Create Publicly Traded, Advanced Clean Energy Buyer: No captured description yet. Target: No captured description yet. | NA | Other | sponsor | Acquisition | 8-K | SEC ↗ |
| 2026-07-10 | InMed Pharmaceuticals Inc. (INM) Buyer: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-10 | Nu-Med Plus, Inc. → Canadian Gold Properties Transaction expected to expand Nu-Med’s operations into gold exploration Buyer: No captured description yet. Target: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-08 | Tarsus Pharmaceuticals, Inc. (TARS) Buyer: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-07 | VERTEX PHARMACEUTICALS INC / MA (VRTX) Buyer: No captured description yet. | $5 billion | Other | strategic | Acquisition | 8-K | SEC ↗ |
| 2026-07-07 | Vivani Medical, Inc. Buyer: No captured description yet. | NA | Other | strategic | Acquisition | 8-K | SEC ↗ |
You are seeing 60 of 1,250 deals
Register to page through the whole tape and search it by acquirer, so you can see who has been buying companies like yours and what they paid. Same page, no paywall, one email a month.
Every acquisition and investment event we can trace to a primary source, newest first, tagged by origin: 8-K and Proxy from EDGAR, Trade press and Deal roundup from named articles (facts extracted, linked for attribution), Adviser and Counsel from the transaction records advisers publish themselves. Sector and buyer type are inferred from SIC and acquirer name. Private-to-private deals that never surface publicly are not captured.